Multimedialna platforma wiedzy medycznej Internetowa Księgarnia Medyczna Kalendarium Konferencji
Palliative Medicine in Practice
MENU
Shortcuts Submit an article Author Guidelines Reviewers 2023 Editorial Team Focus and Scope

open access

Vol 15, No 2 (2021)
Review paper
Published online: 2021-05-20
View PDF Download PDF file
Get Citation

Endocrine and metabolic disorders in cancer patients

Małgorzata Niemiec1, Aleksandra Niemiec2
DOI: 10.5603/PMPI.2021.0012
·
Palliat Med Pract 2021;15(2):203-211.
Affiliations
  1. Department of Surgical Oncology, Department of Oncology, Wroclaw Medical University, Wroclaw, Poland
  2. Uniwersyteckie Centrum Kliniczne im. prof. K. Gibińskiego Śląskiego Uniwersytetu Medycznego w Katowicach, Ceglana 35,, 40-514 Katowice, Poland

open access

Vol 15, No 2 (2021)
Review paper
Published online: 2021-05-20

Abstract

Endocrine and metabolic disorders can occur in the form of paraneoplastic syndrome and as a consequence
of oncological treatment. The most common disorders include hypercalcaemia, ectopic production of vasopressin
in the course of cancer, ectopic Cushing’s syndrome and secondary osteoporosis. What should be
taken into account during the diagnosis of endocrine disorders, is paraneoplastic syndrome that frequently
precedes the occurrence of symptoms typical of a particular diagnosis, which could influence the proper
orientation of the diagnostic process. During and after anticancer treatment, it is recommended that
patients should be monitored for the possible development of acute or chronic metabolic and endocrine
disorders which may pose a threat to their life or health.

Abstract

Endocrine and metabolic disorders can occur in the form of paraneoplastic syndrome and as a consequence
of oncological treatment. The most common disorders include hypercalcaemia, ectopic production of vasopressin
in the course of cancer, ectopic Cushing’s syndrome and secondary osteoporosis. What should be
taken into account during the diagnosis of endocrine disorders, is paraneoplastic syndrome that frequently
precedes the occurrence of symptoms typical of a particular diagnosis, which could influence the proper
orientation of the diagnostic process. During and after anticancer treatment, it is recommended that
patients should be monitored for the possible development of acute or chronic metabolic and endocrine
disorders which may pose a threat to their life or health.

Full Text:

View PDF Download PDF file
Get Citation

Keywords

cancer, palliative care, endocrine disorders, metabolic disorders

About this article
Title

Endocrine and metabolic disorders in cancer patients

Journal

Palliative Medicine in Practice

Issue

Vol 15, No 2 (2021)

Article type

Review paper

Pages

203-211

Published online

2021-05-20

Page views

527

Article views/downloads

512

DOI

10.5603/PMPI.2021.0012

Bibliographic record

Palliat Med Pract 2021;15(2):203-211.

Keywords

cancer
palliative care
endocrine disorders
metabolic disorders

Authors

Małgorzata Niemiec
Aleksandra Niemiec

References (47)
  1. Dec M, Ryczak E, Borowicz B, et al. Zaburzenia hormonalne w chorobach nowotworowych. Oncology and Radiotherapy. 2016; 4(38): 46–49.
  2. Goldner W. Cancer-Related Hypercalcemia. J Oncol Pract. 2016; 12(5): 426–432.
    CrossRefPubMed
  3. Mirrakhimov AE. Hypercalcemia of Malignancy: An Update on Pathogenesis and Management. N Am J Med Sci. 2015; 7(11): 483–493.
    CrossRefPubMed
  4. Sternlicht H, Glezerman IG. Hypercalcemia of malignancy and new treatment options. Ther Clin Risk Manag. 2015; 11: 1779–1788.
    CrossRefPubMed
  5. Zagzag J, Hu MI, Fisher SB, et al. Hypercalcemia and cancer: Differential diagnosis and treatment. CA Cancer J Clin. 2018; 68(5): 377–386.
    CrossRefPubMed
  6. Rucińska M. Stany nagłe w medycynie paliatywnej. In: Ciałkowska-Rysz A, de Walden-Gałuszko K. ed. Medycyna paliatywna. PZWL, Warszawa 2015: 250.
  7. Seccareccia D. Cancer-related hypercalcemia. Can Fam Physician. 2010; 56(3): 244–6, e90.
    PubMed
  8. Misiowski W. Hiperkalcemia. In: Zgliczyński W. ed. Wielka Interna. Endokrynologia. Tom 1. Medical Tribune, Warszawa 2020: 384–391.
  9. Narayanan P. Denosumab: A comprehensive review. South Asian J Cancer. 2013; 2(4): 272–277.
    CrossRefPubMed
  10. Mirza F, Canalis E. Management of endocrine disease: Secondary osteoporosis: pathophysiology and management. Eur J Endocrinol. 2015; 173(3): R131–R151.
    CrossRefPubMed
  11. Roodman GD. Pathogenesis of myeloma bone disease. Leukemia. 2009; 23(3): 435–441.
    CrossRefPubMed
  12. Drake MT. Osteoporosis and cancer. Curr Osteoporos Rep. 2013; 11(3): 163–170.
    CrossRefPubMed
  13. Nishio K, Tanabe A, Maruoka R, et al. Bone mineral loss induced by anticancer treatment for gynecological malignancies in premenopausal women. Endocr Connect. 2013; 2(1): 11–17.
    CrossRefPubMed
  14. Bolanowski M. Osteoporoza wtórna. In: Zgliczyński W. ed. Wielka Interna. Endokrynologia. Tom 1. Medical Tribune, Warszawa 2020: 467–469.
  15. Shapiro CL, Van Poznak C, Lacchetti C, et al. Management of Osteoporosis in Survivors of Adult Cancers With Nonmetastatic Disease: ASCO Clinical Practice Guideline. J Clin Oncol. 2019; 37(31): 2916–2946.
    CrossRefPubMed
  16. Magnowski P, Wolski H, Magnowska M, et al. Bone loss in women with malignant genital neoplasms. Polish Gynaecology. 2014; 85(12): 955–960.
    CrossRef
  17. Lewiecki EM. New and emerging concepts in the use of denosumab for the treatment of osteoporosis. Ther Adv Musculoskelet Dis. 2018; 10(11): 209–223.
    CrossRefPubMed
  18. McDonald P, Lane C, Rojas GE, et al. Syndrome of inappropriate anti-diuretic hormone in non-small cell lung carcinoma: a case report. Ecancermedicalscience. 2012; 6: 279.
    CrossRefPubMed
  19. Castillo JJ, Glezerman IG, Boklage SH, et al. The occurrence of hyponatremia and its importance as a prognostic factor in a cross-section of cancer patients. BMC Cancer. 2016; 16: 564.
    CrossRefPubMed
  20. Marquina G, Gomez-Hoyos E, Runkle I. The management of hyponatremia in cancer patients: a practical view in Spain. Journal of Cancer Metastasis and Treatment. 2020; 2020.
    CrossRef
  21. Castillo JJ, Vincent M, Justice E. Diagnosis and management of hyponatremia in cancer patients. Oncologist. 2012; 17(6): 756–765.
    CrossRefPubMed
  22. Onitilo AA, Kio E, Doi SAR. Tumor-related hyponatremia. Clin Med Res. 2007; 5(4): 228–237.
    CrossRefPubMed
  23. Witek P. Postępy w rozpoznawaniu i leczeniu hiponatremii. Postępy Nauk Medycznych. 2008; 21: 75–82.
  24. Witek P, Misiorowski W, Zgliczyński W. Zespoły ektopowego wydzielania hormonów. In: Zgliczyński W. ed. Wielka Interna. Endokrynologia. Tom 2. Medical Tribune, Warszawa 2020: 259–275.
  25. Cieszyński Ł, Berendt-Obołończyk M, Szulc M, et al. Cushing's syndrome due to ectopic ACTH secretion. Endokrynol Pol. 2016; 67(4): 458–471.
    CrossRefPubMed
  26. Young J, Haissaguerre M, Viera-Pinto O, et al. MANAGEMENT OF ENDOCRINE DISEASE: Cushing's syndrome due to ectopic ACTH secretion: an expert operational opinion. Eur J Endocrinol. 2020; 182(4): R29–R58.
    CrossRefPubMed
  27. Sharma ST, Nieman LK. Cushing's syndrome: all variants, detection, and treatment. Endocrinol Metab Clin North Am. 2011; 40(2): 379–91, viii.
    CrossRefPubMed
  28. Carroll TyB, Peppard WJ, Herrmann DJ, et al. Continuous Etomidate Infusion for the Management of Severe Cushing Syndrome: Validation of a Standard Protocol. J Endocr Soc. 2019; 3(1): 1–12.
    CrossRefPubMed
  29. Juszczak A, Grossman A. Postępowanie w chorobie Cushinga – od testu diagnostycznego do leczenia. Endokrynol Pol. 2013; 64(2): 166–174.
  30. Carvalho F, Louro F, Zakout R. Adrenal Insufficiency in Metastatic Lung Cancer. World J Oncol. 2015; 6(3): 375–377.
    CrossRefPubMed
  31. Papierska L. Niedoczynność kory nadnerczy. In: Zgliczyński W. ed. Wielka Interna. Endokrynologia. Tom 2. Medical Tribune, Warszawa 2020: 22–32.
  32. Ciałkowska-Rysz A. Zaburzenia metaboliczne i hormonalne. In: Ciałkowska-Rysz A, Dzierżanowski T. ed. Medycyna Paliatywna. Termedia, Poznań 2019: 262–265.
  33. Bednarczuk T, Kasperlik–Załuska A. Choroby układu wewnątrzwydzielniczego. In: Interna Szczeklika 2020. Medycyna Praktyczna, Kraków 2020: 1432–1438.
  34. Okabayashi T, Shima Y, Sumiyoshi T, et al. Diagnosis and management of insulinoma. World J Gastroenterol. 2013; 19(6): 829–837.
    CrossRefPubMed
  35. Shin JJ, Gorden P, Libutti SK. Insulinoma: pathophysiology, localization and management. Future Oncol. 2010; 6(2): 229–237.
    CrossRefPubMed
  36. Handkiewicz-Junak D. Nowotwory neuroendokrynne wysoko zróżnicowane. In: Płaczkiewicz-Jankowska E. ed. Interna Szczeklika Mały Podręcznik 2020/2021. Medycyna Praktyczna, Kraków 2020: 887–891.
  37. Garla V, Sonani H, Palabindala V, et al. Non-islet Cell Hypoglycemia: Case Series and Review of the Literature. Front Endocrinol (Lausanne). 2019; 10: 316.
    CrossRefPubMed
  38. Potempa M, Jonczyk P, Zalewska-Ziob M. Endokrynologiczne oblicze raka płuca. Onkol Prakt Klin. 2015; 11(3): 121–128.
  39. Rubin de Celis Ferrari AC, Glasberg J, Riechelmann RP. Carcinoid syndrome: update on the pathophysiology and treatment. Clinics (Sao Paulo). 2018; 73(suppl 1): e490s.
    CrossRefPubMed
  40. Ito T, Lee L, Jensen RT. Carcinoid-syndrome: recent advances, current status and controversies. Curr Opin Endocrinol Diabetes Obes. 2018; 25(1): 22–35.
    CrossRefPubMed
  41. Lewis MA, Hendrickson AW, Moynihan TJ. Oncologic emergencies: Pathophysiology, presentation, diagnosis, and treatment. CA Cancer J Clin. 2011; 61(5): 287–314.
    CrossRefPubMed
  42. Howard SC, Jones DP, Pui CH. The tumor lysis syndrome. N Engl J Med. 2011; 364(19): 1844–1854.
    CrossRefPubMed
  43. Muslimani A, Chisti MM, Wills S, et al. How we treat tumor lysis syndrome. Oncology (Williston Park). 2011; 25(4): 369–375.
    PubMed
  44. Cairo MS, Bishop M. Tumour lysis syndrome: new therapeutic strategies and classification. Br J Haematol. 2004; 127(1): 3–11.
    CrossRefPubMed
  45. Howard SC, Jones DP, Pui CH. The tumor lysis syndrome. N Engl J Med. 2011; 364(19): 1844–1854.
    CrossRefPubMed
  46. Dec M, Ryczak E, Borowicz B. Małecka–Massalska T. Rzadkie zaburzenia hormonalne w chorobach nowotworowych. Oncology and Radiotherapy. 2016; 4(38): 43–45.
  47. Dimitriadis GK, Angelousi A, Weickert MO, et al. Paraneoplastic endocrine syndromes. Endocr Relat Cancer. 2017; 24(6): R173–R190.
    CrossRefPubMed

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By VM Media Group sp. z o.o., ul. Świętokrzyska 73 , 80–180 Gdańsk, Poland

phone:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: viamedica@viamedica.pl